Novel homeobox gene

ABSTRACT

An isolated nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO: 1.

TECHNICAL FIELD

The present invention relates to a novel homeobox gene, the human ortholog of the Aristaless homeobox gene, ARX. The ARX gene has been associated with infantile spasms but, in addition, has been associated with non-specific X-linked mental retardation, X-linked myoclonic epilepsy and Partington syndrome. In view of the realisation that the ARX gene plays a role in these conditions, the mutations responsible have been identified and may be used in their diagnosis.

BACKGROUND ART

Infantile spasms (IS) are a particular form of seizure, usually confined to infancy and often associated with mental retardation. Where IS are associated with hypsarrhythmia (a chaotic brain wave pattern) on electroencephalogram (EEG) and developmental arrest, the term West syndrome is used. IS are often symptomatic of a heterogeneous group of aetiologies such as structural brain malformations or brain injury. A rare subgroup of IS is due to genetic factors (idiopathic IS) and generally has a better prognosis than the symptomatic group. A subgroup of IS is X-linked IS which carries a poor prognosis (ISSX, MIM 308350). The ISSX family of Bruyere et al. initially defined the candidate ISSX gene region to ˜7 Mb, between DXS1226 and AHC (Adrenal Hypoplasia Congenital).

DISCLOSURE OF THE INVENTION

The present invention relates to the human ortholog of the Aristaless homeobox gene, ARX.

According to one aspect of the present invention there is provided an isolated DNA molecule comprising the nucleotide sequence set forth in SEQ ID NO:1, this being the ORF identified in FIG. 1 b. The polypeptide encoded by the gene contains a homeobox domain encompassing amino acid residues 327-386 as shown in FIG. 1 b. As will be appreciated by the person skilled in the art, homeobox domains are very highly conserved over a wide variety of organisms. Proteins containing these types of sequences are thought to be transcription factors, and are important in the regulation of other genes and gene products. Thus, they are involved in the control of many developmental processes, including neuronal development.

The invention also encompasses an isolated DNA molecule which hybridises under stringent conditions with a DNA molecule consisting of the nucleotide sequence set forth in SEQ ID NO:1.

The invention also provides an isolated DNA molecule consisting of the nucleotide sequence set forth in SEQ ID NO:1 or SEQ ID NO:3.

Still further, the invention provides an isolated DNA molecule which encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO:2.

In a further aspect, the present invention provides an isolated ARX gene comprising the nucleotide sequence set forth in FIG. 1 b and appropriate control elements. These may be those naturally-present in the UTR as illustrated in FIG. 1 b and SEQ ID NO:2, or may be non-natural control elements such as exogenous promoters.

According to a further aspect of the present invention, there is provided a mutant ARX whose function has been altered or destroyed.

In a preferred embodiment of the invention there is provided a mutant ARX gene comprising a mutation selected from the group consisting of:

-   -   1) an insertion of trinucleotide repeats coding for additional         alanine residues within a polyalanine tract;     -   2) a duplication coding for additional alanine residues within a         polyalanine tract;     -   3) a deletion; and     -   4) a missense mutation within the homeobox.

In a particularly preferred embodiment, the mutations are selected from the group consisting of

-   -   (i) an insertion of (GCG)₇ trinucleotide repeats within the         first polyalanine tract;     -   (ii) a 24 bp duplication coding for 8 additional alanine         residues in the second polyalanine tract;     -   (iii) a deletion encompassing exon 5; and     -   (iv) a 1058 C>T missense mutation,

as set forth in SEQ ID NOs:4, 5, 6 and 7, respectively, and whose expression products are shown in SEQ ID Nos:8, 9, 10 and 11.

According to a further aspect of the present invention, there is provided an isolated polypeptide comprising the amino acid sequence set forth in FIG. 1 b.

The invention also encompasses an isolated polypeptide having at least 70%, preferably 85% and more preferably 95% identity outside of the homeodomain with the amino acid sequence set forth in FIG. 1 b, and the polypeptides encoded by the mutant ARX genes described above.

Amino acid sequence variants of ARX are prepared by introducing appropriate nucleotide changes into DNA, and subsequently expressing the resulting modified DNA in a host cell, or alternatively may be prepared by in vitro synthesis. Such variants include deletions, insertions or substitutions of amino acid residues within the amino acid sequence set out in SEQ ID NO: 2. Any combination of deletion, insertion, and substitution may be made to arrive at an amino acid sequence variant of ARX, provided that the variant possesses the desired functional characteristics described herein. There are two principal variables in the construction of amino acid sequence variants of a peptide: the location of the mutation site and the nature of the mutation. In general, the location and nature of the mutation chosen will depend upon the characteristic to be modified.

For example, due to the degeneracy of nucleotide coding sequences, mutations can be made in the ARX nucleotide sequence without affecting the amino acid sequence of the product encoded by this sequence. Other mutations can be made which will result in a peptide which has an amino acid sequence different from that set out in SEQ ID NO: 2, but which is functionally active. Such functionally active amino acid sequence variants of XXXX are selected, for example, by substituting one or more amino acid residues in the amino acid sequence set out in SEQ ID NO: 2 with other amino acid residues of a similar or different polarity or charge.

In a further aspect of the present invention, there is provided a method of preparing ARX or a variant thereof as described above, comprising the steps of:

-   -   culturing host cells transformed with the DNA molecule as         described above under conditions effective for the production of         polypeptides; and     -   harvesting the polypeptides.

In a still further aspect of the present invention, there is provided host cells transformed with a DNA molecule as described above.

In a still further aspect of the present invention, there is provided an animal model in which a wild-type mutant DNA molecule as described above is expressed, or the ARX gene is knocked out.

The present invention also provides a means for the diagnosis of the conditions described above. Accordingly, in a further aspect of the present invention, there is provided the use of a DNA molecule as described above or a polypeptide as described above in the diagnosis of diseases associated with mutation in the ARX gene. In particular, these molecules are useful in the correct diagnosis of infantile spasms, X-linked mental retardation, X-linked myoclonic epilepsy, Partington syndrome and dystonia. Screening of individuals without these diseases may also be conducted, particularly of relatives of affected people, in order to establish whether they carry the mutation, and pre-natal and pre-implantation testing are also envisaged.

Throughout this specification and the claims, the words “comprise”, “comprises” and “comprising” are used in a non-exclusive sense, except where the context requires otherwise.

It will be clearly understood that, although a number of prior art publications are referred to herein, this reference does not constitute an admission that any of these documents forms part of the common general knowledge in the art, in Australia or in any other country.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 a. ISSX candidate gene region in Xp22. The minimal ˜7 cM ISSX candidate gene region between the markers DXS1226 and AHC is shown. Known genes and STS's from the region are indicated. Position and orientation of ARX with respect to the POLA gene is highlighted. Genank accession numbers for genomic sequences for these two genes are shown. The cen-to-tel orientation of the POLA-ARX region is shown as annotated in Ensembl. The map is not drawn to scale. b. cDNA and protein sequence of the human ARX gene. Sequence of the ARX cDNA is shown. Untranslated regions (5′UTR-incomplete, and 3′ UTR) are in lowercase letters, ORF is in uppercase letters. The numbers on the right correspond to the cDNA/ORF, as well as translated ARX protein sequence positions, respectively. Exon/exon boundaries are indicated with asterisks (*). The canonical polyadenylation signal (AATAAA) is in uppercase letters and underlined (position 2705-2709). Two homogeneous GC-rich trinucleotide repeats, (GCG)₁₀ and (GCC)₇, are boxed. Four polyA tracts are underlined with those harboring mutations boxed. The 24 bp region of duplication (428-451 dup (24 bp) and 1 517-bp deletion of intron 4 and exon 5 of ARX of the small ISSX family (IVS4-816_EX5701del/483fs) are boxed. The point mutation found in the myoclonic epilepsy family (1058C>T, P313L) is highlighted by a black box within the homeodomain of the ARX protein (boxed amino acid residues 327-386, P26 residue of the homeodomain). The other two conserved domains of the paired type homoebox proteins, the octapeptide (amino acids 25-34) and the aristaless domain (amino acids 527-562) are boxed. ARX nuclear localisation sequence (NLS) PPKLRRLY (position 82-89) is circled.

FIG. 2. The ARX gene mutations affecting polyA tracts. a, DNA sequence chromatograms showing the (GCG)₁₀₊₇; and b, the 428-451 dup (24 bp) mutations, respectively. Protein translation and amino acid position is indicated above and the cDNA sequence and ORF position of ARX below the chromatograms. The extra alanine (A) residues of the ARX protein resulting from these two mutations are highlighted by rounded rectangles. The expansion of (GCG)₇ and duplication of 24 bp are indicated by arrows. Empty and solid squares indicate normal and affected male chromosomes. Asterisks indicate altered amino acid and cDNA positions of the ARX gene as a consequence of the two mutations.

FIG. 3. ARX mutation 1058C>T (P353L). a, Partial sequence chromatograms of exon 2 of ARX of one affected male (left), one carrier female (middle), and a normal male (right) are shown. The position of the mutation is indicated with an arrow. Resulting amino acid sequence is shown above the chromatograms with the resulting proline (P)-to-leucine (L) change highlighted. b, Part of the large pedigree of the myoclonic epilepsy family showing the co-segregation of the 1058C>T mutation with the affected status in this family. Corresponding part of exon 2 of ARX was amplified from genomic DNA and digested with the MspI restriction enzyme to distinguish between the normal (presence of 9 MspI restriction enzyme sites) and 1058C>T mutated chromosome (abolishing the most 3′-end site and thus generating a large 220-bp product instead of two 162-bp and 58-bp products-indicated with an asterisk). Sizes of the resulting restriction fragments are indicated. The primers used in this experiment are those used for genomic PCR and sequencing of exon 2 (2P2F and 2P2R, see Materials and Methods). c, ClustalW alignment of the paired type homeodomain of the normal human ARX (Homo sapiens) protein, the P353L mutation, mouse (Arx, Mus musculus), zebrafish (Arx, Danio rerio), sea urchin (Arx-like, Strongylocentrotus purpuratus), fly (Al, Drosophila melanogaster), and polyp (prdl-a, Hydra vulgaris) orthologs, and other representatives of the aristaless-related proteins (SHOX, ALX3 from Group I; OTP and Rx from Group II (ARX is a member of this group); and PITX1 from Group III; classification according to ref.18). The invariant proline P353 residue (P26 of the homeodomain) is boxed and indicated with an arrow. On the alignment the residues, which differ from the consensus are shown on a black background, this includes the P353L mutation as identified in the myoclonic epilepsy family in this study.

MODES FOR PERFORMING THE INVENTION

Preferred embodiments of the invention will now be described, by way of example only, with reference to the Figures.

The terms “cell,” “host cell,” “cell line,” and “cell culture” are used interchangeably, and all such terms should be understood to include progeny of the cells.

“Control sequences” refers to DNA sequences necessary for the expression of an operably linked nucleotide coding sequence in a particular host cell. Control sequences suitable for expression in prokaryotes include origins of replication, promoters, ribosome binding sites, and transcription termination sites. Control sequences suitable for expression in eukaryotes include origins of replication, promoters, ribosome binding sites, polyadenylation signals, and enhancers.

An “exogenous” element is one that is foreign to the host cell, or homologous to the host cell but in a position within the host cell in which the element is ordinarily not found.

“Polymerase chain reaction,” or “PCR,” as used herein generally refers to a method for amplification of a desired nucleotide sequence in vitro, as described in U.S. Pat. No. 4,683,195. In general, the PCR method involves repeated cycles of primer extension synthesis, using two oligonucleotide primers capable of hybridizing preferentially to a template nucleic acid. Typically, the primers used in the PCR method will be complementary to nucleotide sequences within the template at both ends of or flanking the nucleotide sequence to be amplified, although primers complementary to the nucleotide sequence to be amplified also may be used. See Wang, et al., in PCR Protocols, pp.70-75 (Academic Press, 1990); Ochman, et al., in PCR Protocols, pp. 219-227; Triglia, et al., Nuc. Acids Res. 16:8186 (1988).

“PCR cloning” refers to the use of the PCR method to amplify a specific desired nucleotide sequence present amongst the nucleic acids from a suitable cell or tissue source, including total genomic DNA and cDNA transcribed from total cellular RNA. See Frohman, et al., Proc. Mat. Acad. Sci. USA 85:8998-9002 (1988); Saiki, et al., Science 239:487-492 (1988); Mullis, et al., Meth. Enzymol. 155:335-350 (1987).

“Stringent conditions” for hybridization or annealing of nucleic acid molecules are those that

-   -   (1) employ low ionic strength and high temperature for washing,         for example 0.015 M NaCl/0.0015 M sodium citrate/0.1% sodium         dodecyl sulfate (SDS) at 50 □C, or     -   (2) employ during hybridization a denaturing agent such as         formamide, for example 50% (vol/vol) formamide with 0.1% bovine         serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium         phosphate buffer at pH 6.5 with 750 mM NaCl, 75 mM sodium         citrate at 42 □C. Another example is use of 50% formamide, 5×SSC         (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate         (pH 6.8), 0.1% sodium pyrophosphate, 5× Denhardt's solution,         sonicated salmon sperm DNA (50 □g/mL), 0.1% SDS, and 10% dextran         sulfate at 42 □C, with washes at 42 □C in 0.2×SSC and 0.1% SDS.

“ARX nucleic acid” is RNA or DNA which encodes ARX. “ARX DNA” is DNA which encodes ARX. ARX DNA is obtained from cDNA or genomic DNA libraries, or by in vitro synthesis. Identification of ARX DNA within a. CDNA or a genomic DNA library, or in some other mixture of various DNAs, is conveniently accomplished by the use of an oligonucleotide hybridization probe that is labeled with a detectable moiety, such as a radioisotope. See Keller, et al., DNA Probes, pp.149-213 (Stockton Press, 1989). To identify DNA encoding ARX, the nucleotide sequence of the hybridization probe is preferably selected so that the hybridization probe is capable of hybridizing preferentially to DNA encoding the ARX amino acid sequence set out in SEQ ID NO:2, or a variant or derivative thereof as described herein, under the hybridization conditions chosen. Another method for obtaining ARX nucleic acid is chemically synthesis, for example using one of the methods described by Engels, et al., Agnew. Chem. Int. Ed. Engl. 28:716-734 (1989).

If the entire nucleotide coding sequence for ARX is not obtained in a single cDNA, genomic DNA, or other DNA, as determined by DNA sequencing or restriction endonuclease analysis, then appropriate DNA fragments (e.g., restriction fragments or PCR amplification products) may be recovered from several DNAs and covalently joined to one another to construct the entire coding sequence. The preferred means of covalently joining DNA fragments is by ligation using a DNA ligase enzyme, such as T4 DNA ligase.

“Isolated” ARX nucleic acid is ARX nucleic acid which is identified and separated from, or otherwise substantially free from, contaminant nucleic acid encoding other polypeptides. The isolated ARX nucleic acid can be incorporated into a plasmid or expression vector, or can be labeled for diagnostic and probe purposes, using a label as described further.

For example, isolated ARX DNA, or a fragment thereof comprising at least about 15 nucleotides, is used as a hybridization probe to detect, diagnose, or monitor disorders or diseases that involve changes in ARX expression.

Preliminary transcriptional mapping of the minimal ISSX interval identified only ˜20 genes. The human Aristaless related homeobox gene (ARX) was identified in the genomic sequence of the PAC clone 258N20 (GenBank AC002504), in the vicinity of the POLA (DNA polymerase alpha) gene (FIG. 1 a). The ARX gene was screened for mutations in five families. In four of these families alterations of the ARX sequence were detected. In the family of Bruyere et al. (ref. 9), and family A of Claes et al. (ref. 11) an additional stretch of (GCG)₇ repeats within the normal repeat size of (GCG)₁₀ (exon 2) was found (FIG. 1 b and 2 a). In the family B of Claes et al. (ref. 11) no mutation was found. The family of Strømme et al. (ref. 10) had a duplication of 24 bp (428-451 dup (24 bp) of exon 2 (see FIG. 1 b and 2 b). This 24-bp sequence is an almost perfect inverted repeat. A small Norwegian family was found to have a deletion of 1 517 bp, which removes 816 bp of intron 4 and 701 bp of exon 5 (IVS4-816_EX5701de1). This deletion results in an alternate COOH end of the ARX protein (R483fs; FIG. 1 b). Both the expansion (GCG)₁₀₊₇ and the duplication mutations are predicted to cause expansions of two different polyalanine (polyA) tracts of the ARX protein. For the former mutation the normal 16 A tract (amino acid positions 100-115) is expanded to 23, and for the latter the normal 12 A tract (amino acid positions 144-155) is expanded to 20 (FIG. 2 a and b). No such changes of the ARX gene were detected on more than 300 control chromosomes screened. The (GCG) repeat was found to be invariable.

Previously, genes mutated in syndromic X-linked mental retardation (XLMR) have also been shown to carry mutations responsible for other syndromic (MRXS) as well as non-specific forms (MRX; for review see refs 1 and 12). Consequently the ARX gene was screened in six Xp22-linked XLMR families with various clinical manifestations. Two families with MRX (MRX-M and MRX-E), two families with MR and dystonic movements of the hands (Partington syndrome, PRTS MIM 309510; ref. 13 and S.F), one family with mental retardation and a history of hypsarrhythmia (MRXS-B), and one family with myoclonic epilepsy, intellectual disability and spasticity were screened. The results of this screening were as follows. One of the two MRX families (MRX-M) and both PRTS families were found to have the same duplication of the 24 bp of exon 2 as the family of Strømme et al (ref. 10). i.e. 428-451 dup (24 bp). There was no mutation found in the second MRX family (MRX-V) tested. Screening of the X-linked myoclonic epilepsy family identified a missense mutation at nucleotide position 1058, 1058C>T (FIG. 3 a and b). This mutation is predicted to cause a change of proline 353 to leucine (P353L). The P353 residue is highly conserved and is one of the six invariant residues typical of the paired type of homeodomain (P26 residue; FIG. 3 c). Based on the highly conserved nature of this P353 and the fact that a similar change has not been found on at least 100 control X-chromosomes tested, we predict that this represents a novel ARX gene mutation.

To test the possibility that the identical mutations, i.e. (GCG)₁₀₊₇ and 428-451 dup (24 bp), were derived from founder chromosome(s), haplotype analysis using closely linked flanking STS markers was performed. Four markers from the region were used; two distal DXS8099 and DXS8027 (˜500 and 220 kb distal to ARX), and two proximal DXS8047 and DXS1202 (˜300 and 600 kb proximal to ARX). The identical ARX mutations were all on different haplotypes. This supports independent, de novo origins of identical mutations in each family. We speculate that the recurrence of the 428-451 dup (24 bp) mutation may be due to the inverted repeat nature of the duplicated 24-bp sequence and its consequent instability, as indicated by our inability to clone the 428-451 dup (24 bp) mutation in E. coli. The apparently invariant (GCG)₁₀ repeat expanded by (GCG)₇ in two cases. Such repeats are known to form secondary structures, which solely or in addition to other cis- and trans-acting factors could contribute to repeat expansion.

ARX is a novel human homeodomain containing gene. In order to characterize it, we have used available genomic, EST and protein database resources (see Materials and Methods). The ARX gene is located about 6.7 kb from the 3′ end of the POLA gene (tail-to-tail orientation; Fig 1 a) and encompasses a genomic region of about 12.5 kb. It is composed of 5 coding exons and is transcribed into a ˜2.8-kb mRNA (FIG. 1 b). The open reading frame is 1 686-bp long and encodes a protein of 562 amino acids. Preliminary analysis of the expression of the human ARX gene by. human multiple tissue Northern blot and EST analysis indicates that it is expressed predominantly in fetal and adult brain (occipital, frontal, and temporal lobes of the cerebral cortex, amygdala, corpus callosum, caudate nucleus and hippocampus) and skeletal muscle. While in brain only a single ARX mRNA isoform was detected, skeletal muscle showed two additional, smaller ARX mRNAs, the origin of which remains to be determined.

The mouse and zebra fish ARX orthologs have been characterized by in situ hybridization to be expressed predominantly in forebrain (cerebral cortex) and floor plate. This expression pattern may suggest an important role for the ARX protein in the maintenance of specific neuronal subtypes in the cerebral cortex and axonal guidance in the floor plate.

The ARX protein belongs to a subset of Aristaless-related Paired-class homeodomain proteins. Homeobox containing genes have been shown to participate in crucial developmental decisions. While not wishing to be bound by theory, it is believed that Aristaless-related homeobox genes might regulate essential events during vertebrate embryogenesis and head development in particular. The Aristaless-related class of homeodomain proteins is characterized by either a Paired/Q50 or Paired/K50 homeodomain and a C-terminal domain called the aristaless domain (also known as OAR domain, C-peptide, or ‘Paired tail’). The functionally characterized domains of the ARX protein are annotated in FIG. 1 b. Comparison of the ARX protein to its partially characterized vertebrate orthologs reveals 94.3% and 57.2% identity with mouse and zebrafish, respectively. The octapeptide, nuclear localization sequence (NLS) and homeobox domains are identical, while the C-terminal aristaless domain is identical between human and mouse and highly similar (87%) between human/mouse and zebrafish. Conservation in the regions of the expanded polyA tracts (amino acids 100-115 and 144-155 on human ARX) between human and mouse is not 100% and the two tracts are entirely absent in zebrafish. There are two additional polyA tracts within the ARX protein (amino acids 275-281 and 431-439; FIG. 1 b), with only the C-terminal tract being highly conserved. The function of such extended polyA tracts, common among homeobox and other transcription factor proteins, is not known, but it has been suggested that such tracts might suppress transcription.

There appears to be a positive correlation between the length of the polyA expansion and the severity of the disorder. Our results provide evidence that (GCG)₁₀₊₇ mutations, causing expansion from 16 to 23 Ala in the ISSX families, are of a more severe nature than those caused by the 428-451 dup (24 bp) mutations (from 12 to 20 Ala). Experiments with green fluorescent protein tagged polyA peptides of various lengths further support this correlation and suggest a threshold for aggregate formation of between 7 and 19 alanine residues.

The family of human homeodomain-containing genes has at least 129 members spread throughout the genome. The highly conserved 180-bp homeobox region encodes a helix-turn-helix motif known to bind specific DNA sequences. Homeodomain proteins function as crucial developmental transcription factors. Mutations of several homeobox-containing genes are known to cause human disease. The 1058C>T/P353L mutation of the myoclonic epilepsy family is the only homeodomain mutation found in this study. Although not directly involved in the homeodomain target sequence recognition, this residue is predicted to play an important role in the homeodomain structure determination by providing the proper hydrophobic environment.

The phenotypic variability of profound to mild mental retardation, infantile spasms, myoclonic epilepsy, or dystonia, associated with rather different ARX gene mutations is striking and difficult to explain. In our cohort of patients from nine families with ARX gene mutations we collected data on 51 affected individuals; 57% had seizures of various types, most commonly infantile spasms. All patients had clearly identified mental retardation with ˜⅔ in the moderately to profoundly impaired range. Additional neurological abnormalities associated with ARX mutations included micro and macrocephaly, hypotonia, spasticity, and ataxia. From among the mutations found, the IVS4-816_EX5701del/R483fs mutation caused perhaps the most severe phenotype with severe developmental delay, infantile spasms, microcephaly and spasticity. The severity of the two polyA mutations, (GCG)¹⁰⁺⁷ and 428-451 dup (24 bp) was similar although especially for the latter one, the range of clinical manifestations was broad, including ISSX, PRTS, MRX and MRXS. The phenotype of the 1058C>T/P353L mutation shared similarities with the phenotypes described above with MR, early onset of seizures (3 months to 2 years), and hypsarrhythmia in some males, but differed with myoclonic epilepsy and spasticity being prominent features.

Identification of the ARX gene represents identification of i, the first gene for idiopathic infantile spasms; ii, a new class of gene for idiopathic epilepsy, other than an ion channel; iii, one of a group of genes involved in both syndromic and non-specific XLMR; and iv, a new gene implicated in dystonia. ARX represents an X-linked gene of major significance to human cognitive function, similar to FM1, FMR2, ATRX, or MECP2 (ref.1). The ARX gene is readily amenable to screening in the same patient group with developmental delay that is now routinely tested for fragile X syndrome as described, for example, in U.S. Pat. No. 6,197,500, the contents of which are incorporated herein by reference.

A probe is designed and used for diagnosis (e.g., prenatal diagnosis or carrier detection) by standard technology utilizing means to detect hybridization of the probe under appropriate stringency conditions to the abnormal sequence. Any suitable means for detection of hybridization can be used, including radioactive or fluorescent labeling of the probe. For effective use as a probe, a fragment of the 150 kb segment may be 10 to 10,000 nucleotides in length, preferably 50 to 1000 nucleotides in length, more preferably 100 1000 nucleotides in length. The probe may be prepared by enzymatic digestion of a larger fragment of DNA or may be synthesized.

There are many different types of DNA mutations. They can be stratified based on the type of the defect as: large deletions (in tens to hundreds base pairs), small deletions (ibase pair to tens base pairs), single nucleotide changes (missense, silent and non-sense), duplications and inversions. Most of these can be found in exons, but not only. Often intronic mutations are present, some 5′ and 3′ UTR mutations as well as promoter mutations.

Based on the type of the mutation (and the required throughput/detection rate) a particular technique is employed. There are techniques which scan for known (previously detected) mutations like direct DNA sequencing, SSCP—single strand conformational polymorphism analysis, DGGE—denaturing gradient gel electrophoresis (ref 33), allele specific PCR, DHPLC—denaturing high-performance liquid chromatography (ref 55), MALDI TOF MS—Matrix-assisted laser desorption/ionization-time of flight mass spectrometry (ref 34), microarrays (ref 37), or Southern blot techniques.

Mutation screening strategy for research purposes (low throughput, high mutation detection rate, high cost/sample) often differs from mutation detection for diagnostic applications (high throughput, moderate mutation detection rate, low cost/sample).

Which technique is applied for diagnostic or screening purposes depends on a particular mutation. For example, the ARX duplication mutation (428-451 dup 24bp) and the GCG insertion (GCG10+7) can easily be detected using SSCP, agarose gel electrophoresis, or DHPLC. Point mutation like 1058C>T can be detected by SSCP and DHPLC, but also using array technology.

Array technology has the power to screen for any single nucleotide change in a given sequence (for example the Affymetrics type DNA chip). Therefore, it is convenient to use a microarray (Ref 37) comprising probes according to the invention for diagnosis. Typically, the microarray will comprise wild-type and mutated ARX oligonucleotides. Hybridization of patient DNA to such an array is detected and pattern generated is scored from wild-type versus mutated oligonucleotides (all possible variations) to identify the altered nucleotide.

Further, by altering the stringency of the conditions of hybridization the sequences corresponding to the locus can be isolated from normal subjects, sequenced, and corresponding sequences used in genetic therapy to correct this defect. Thus, the present invention also provides a method to treat ARX-related disorders which method comprises replacing, repairing or compensating a mutant ARX gene of the X chromosome of a subject with the corresponding DNA of a normal chromosome.

Oligonucleotides for use as hybridization probes or primers may be prepared by any suitable method, such as by purification of a naturally-occurring DNA or by in vitro synthesis. For example, oligonucleotides are readily synthesized using various techniques in organic chemistry, such as those described by Narang, et al., Meth. Enzymol. 68:90-98 (1979); Brown, et al., Meth. Enzymol. 68:109-151 (1979); Caruther, et al., Meth. Enzymol. 154:287-313 (1985). The general approach to selecting a suitable hybridization probe or primer is well known; see Keller, et al., DNA Probes, pp.11-18 (Stockton Press, 1989). Typically, the hybridization probe or primer will contain 10-25 or more nucleotides, and will include at least 5 nucleotides on either side of the sequence encoding the desired mutation so as to ensure that the oligonucleotide will hybridize preferentially to the single-stranded DNA template molecule.

The availability of cloned sequences from the ARX locus also makes possible the identification of a protein product encoded by the cloned sequences. Such proteins may be identified by operably linking the cloned sequences to a promoter in an expression vector. Many appropriate expression vectors for this purpose are widely known in the art. See, for example, Sambrook, et al., Molecular Cloning: A Laboratory Manual, 1990, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. The protein product may be used for diagnostic or therapeutic purposes. Thus, for example, the presence, absence, or alteration of the protein product may correspond to the status of an affected individual. Similarly, the protein product from a normal individual may be used to treat an affected individual with an altered protein product.

Isolated ARX nucleic acid may be used to produce ARX by recombinant DNA and recombinant cell culture methods. In various embodiments of the invention, host cells are transformed or transfected with recombinant DNA molecules comprising an isolated DNA of the invention, to obtain expression of the DNA and thus the production of ARX in large quantities. DNA encoding amino acid sequence variants of ARX is prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source (in the case of naturally-occurring amino acid sequence variants of ARX or preparation by site-directed (or oligonucleotide-mediated) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared DNA encoding a variant or a non-variant form of ARX.

Site-directed mutagenesis is a preferred method for preparing substitution, deletion, and insertion variants of ARX DNA. Briefly, in carrying out site-directed mutagenesis of ARX DNA, the DNA is altered by first hybridizing an oligonucleotide encoding the desired mutation to a single strand of such DNA. After hybridization, a DNA polymerase is used to synthesize an entire second strand, using the hybridized oligonucleotide as a primer, and using the single strand of DNA as a template. Thus, the oligonucleotide encoding the desired mutation is incorporated in the resulting double-stranded DNA.

DNA, whether cDNA or genomic DNA or a product of in vitro synthesis, may be ligated into a replicable vector for further cloning or for expression. “Vectors” are plasmids and other DNAs that are capable of replicating autonomously within a host cell, and as such, are useful for performing two functions in conjunction with compatible host cells (a vector-host system). One function is to facilitate the cloning of the nucleic acid that encodes the gene product, i.e., to produce usable quantities of the nucleic acid. The other function is to direct the expression of the gene product. One or both of these functions are performed by the vector-host system. The vectors will contain different components, depending upon the function they are to perform as well as the host cell with which they are to be used for cloning or expression.

To produce ARX or its variants, an expression vector will contain nucleic acid that encodes the desired product, as described above. In one example of recombinant host cell expression, mammalian cells are transfected with an expression vector comprising ARX DNA and the product is recovered from the culture medium in which the recombinant host cells are grown. It will be clearly understood that the expression vectors and methods disclosed herein are suitable for use over a wide range of prokaryotic and eukaryotic organisms.

Various methods of transformation and transfection are available, depending on the nature of the host cell. In the case of E. coli cells, the most common methods involve treating the cells with aqueous solutions of calcium chloride and other salts. In the case of mammalian cells, the most common methods are transfection mediated by either calcium phosphate or DEAE-dextran, or electroporation. See Sambrook, et al., eds., Molecular Cloning, pp. 1.74-1.84 and 16.30-16.55 (Cold Spring Harbor Laboratory Press, 1989). Following transformation or transfection, the desired nucleic acid may integrate into the host cell genome, or may exist as an extrachromosomal element.

Host cells transformed or transfected with the above-described plasmids and expression vectors are cultured in conventional nutrient medium modified as is appropriate for inducing promoters or selecting for drug resistance or some other selectable marker or phenotype. The culture conditions, such as temperature, pH, and the like, suitably are those previously used for culturing the host cell used for cloning or expression, as the case may be, and will be apparent those skilled in the art.

Suitable host cells for cloning or expressing the vectors herein are prokaryotes, yeasts, and higher eukaryotes, including insect, vertebrate, and mammalian host cells.

Furthermore, monoclonal or polyclonal antibodies against the protein product may be raised by a wide variety of techniques widely known in the art. These antibodies may be labeled and used in a variety of immunoassays, or, as described above, for therapeutic use in an affected individual. See, for example, Harlow, et al., Antibodies: A Laboratory Manual, 1988, Cold Spring Harbor Press, Cold Spring Harbor, N.Y.

ARX or its variants may be used as an immunogen to generate anti-ARX antibodies. Such antibodies, which specifically bind to ARX, are useful as standards in assays for ARX, such as by labeling purified ARX for use as a standard in a radioimmunoassay, enzyme-linked immunoassay, or competitive-type receptor binding assays radioreceptor assay, as well as in affinity purification techniques. Ordinarily, the anti-ARX antibody will bind ARX with an affinity of at least about 10⁶ L/mole, and preferably at least about 10⁷ L/mole.

Polyclonal antibodies directed toward ARX generally are raised in animals by multiple subcutaneous or intraperitoneal injections of ARX and an adjuvant. It may be useful to conjugate ARX or a peptide fragment thereof to a carrier protein that is immunogenic in the species to be immunized, such as keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, or soybean trypsin inhibitor.

Monoclonal antibodies directed toward ARX are produced using any method which provides for the production of antibody molecules by continuous cell lines in culture. The modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. Examples of suitable methods for preparing monoclonal antibodies include the original hybridoma method of Kohler, et al., Nature 256:495-497 (1975), and the human B-cell hybridoma method, Kozbor, J. Immunol. 133:3001 (1984); Brodeur, et al., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987).

The monoclonal antibodies of the invention specifically include “chimeric” antibodies (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (Cabilly, et al., U.S. Pat. No. 4,816,567; Morrison, et al., Proc. Natl. Acad. Sci. 81:6851-6855 (1984)).

The chimeric antibody may be a “humanized” antibody. Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as “import” residues, which are typically taken from an “import” variable domain.

Humanization can be performed following methods known in the art (Jones, et al., Nature 321:522-525 (1986); Riechmann, et al., Nature, 332:323-327 (1988); Verhoeyen, et al., Science 239:1534-1536 (1988)), by substituting rodent complementarity-determining regions (CDRs) for the corresponding regions of a human antibody. Alternatively, it is now possible to produce transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production. For example, it has been described that the homozygous deletion of the antibody heavy-chain joining region (J_(H)) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the production of human antibodies upon antigen challenge. See, for example, Jakobovits, et al., Proc. Natl. Acad. Sci. 90: 2551-2555 (1993); Jakobovits, et al., Nature 362:255-258 (1993); Bruggermann, et al., Year in Immuno. 7:33 (1993). Human antibodies can also be produced in phage-display libraries (Hoogenboom, et al., J. Mol. Biol. 227:381 (1991); Marks, et al., J. Mol. Biol. 222:581 (1991).

For diagnostic applications, anti-ARX antibodies typically will be labeled with a detectable moiety. The detectable moiety can be any one which is capable of producing, either directly or indirectly, a detectable signal. For example, the detectable moiety may be a radioisotope, such as ³H, ¹⁴C , ³²P, ³⁵S, or ¹²⁵I, a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin; radioactive isotopic labels, such as, e.g., ¹²⁵I, ³²p, ¹⁴C, or ³H, or an enzyme, such as alkaline phosphatase, beta-galactosidase or horseradish peroxidase.

Any method known in the art for separately conjugating the antibody to the detectable moiety may be employed, including those methods described by David, et al., Biochemistry 13:1014-1021 (1974); Pain, et al., J. Immunol. Meth. 40:219-231 (1981); and Bayer, et al., Meth. Enz. 184:138-163 (1990).

The anti-ARX antibodies may be employed in any known assay method, such as competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays. Zola, Monoclonal Antibodies: A Manual of Techniques, pp.147-158 (CRC Press, Inc., 1987). Neutralizing anti-ARX antibodies are useful as antagonists of ARX.

Methods

ISSX Families

Four large, mapped X-linked families were analyzed. These included two families of Claes et al. (ref. 11), and one family each from Strømme et al. (ref. 10) and Bruyere et al. (ref. 9). Another small family with infantile spasms from Norway was available for analysis. The patient is a 2-year-old boy whose development from birth was severely delayed with lack of eye contact, poor head control, decreased limb movements, and increased muscle tone. Seizures were noted at 4½ weeks progressing to culminant infantile spasms with hypsarrhythmia, refractory to vigabatrin, ACTH, and multiple antiepileptic drugs. During the first year microcephaly with unilateral flattening of the skull, right microphthalmia and delayed myelination on MRI were observed. One maternal uncle died at 20 months of age with infantile spasms and severe developmental delay.

Bioinformatic Analyses

The map of the candidate ISSX/WS DXS1226/AHC ˜7 cM region was initially accessed at the Baylor College of Medicine URL site (http://kiwi.imgen.bcm.tmc.edu:8088/cgi-bin/seq/home/) and further refined using Ensembl at: http://www.ensembl.org/. Genomic sequence of the PAC RPCI1-258N20 was masked for repeat sequences using Repeat Masker at http://ftp.genome.washington.edu/cgi-bin/RepeatMasker. Masked sequence was searched against nr and EST divisions of the GenBank database using Blast (http://www.ncbi.nlm.nih.gov/cgi-bin/BLAST/). DNA and protein sequences of the known genes as well as ESTs (GenBank; http://www.ncbi.nlm.nih.gov/), and Unigene clusters (http://www.ncbi.nlm.nih.gov/UniGene/index.html) were downloaded and further manipulated using the Lasergene software package (DNA Star).

Mutation Search

Primer pairs were designed from the genomic sequence flanking each of the five exons of the ARX gene. For exon 2 two overlapping PCR products P1 and P2 were designed. The primers, T_(m) for the annealing step of the PCR and sizes of the genomic. PCR products were as follows: exon 1, 520-bp product (T_(m)=63° C.), 1F (5′-GCTCACTACACTTGTTACCGC-3′-SEQ ID NO:12) and 1R (5′-AATTGACAATTCCAGGCCACTG-3′-SEQ ID NO:13); exon 2P1, 584-bp product (T_(m)=62° C.), 2P1F (5′-ACGCCTGGGCCTAGGCACTG-3′-SEQ ID NO:14) and 2P1R (5′-CTCGGTGCCGGTGCCACCAC-3′-SEQ ID NO:15); exon 2P2, 602-bp product (T_(m)=62° C.) , 2P2F (5′-GCAAGTCGTACCGCGAGAACG-3′-SEQ ID NO:16) and 2P2R (5′-TGCGCTCTCTGCCGCTGCGA-3′-SEQ ID NO:17); exon 3, 231-bp product (T_(m)=60° C.) , 3F (5′-GAAATAGCTGAGAGGGCATTGC-3′-SEQ ID NO:18) and 3R (5′-TCTCTTGGTTTTGTGAAGGGGAT-3′-SEQ ID NO:19); exon 4, 551-bp product (T_(m)=60° C.) , 4F (5′-GACGCGTCCGAAAACAACCTGAG-SEQ ID NO:20) and 4R (5′-CCCCAGCCTCTGTGTGTATG-3′-SEQ ID NO:21); and exon 5, 347-bp product (T_(m)=60° C.) , 5F (5′-ACAGCTCCCGAGGCCATGAC-3′-SEQ ID NO:22) and 5R (5′-GAGTGGTGCTGAGTGAGGTGA-3′-SEQ ID NO:23). We found the PCR amplification of the ARX exons of poor reproducibility due most probably to an unusually high GC content. Ultimately we have optimized the conditions using Failsafe buffer J (EPICENTRE Technologies) and Expand Long Template Enzyme Mix (Roche). Usually up to 35 PCR cycles of denaturation at 94° C. for 30 sec, annealing at 60-63° C. for 30 sec and extension at 68° C. for 2 min were carried out on 50-100 ng of genomic DNA with 0.5 μM PCR primers, 200 mM dNTPs, 2.5 U of Expand Long Template Enzyme Mix (Roche), and lx Failsafe buffer J (EPICENTRE Technologies).

As controls, 300 chromosomes were tested by denaturing polyacrylamide electrophoresis (5% gel) for the presence of either the (GCG)₁₀₊₇ or 428-451 dup (24 bp) exon 2 ARX mutations. There were no such alleles detected in this sample set. It is also notable that the homogeneous repeat (GCG)₁₀ (position 314-333) is invariable as all chromosomes tested showed only the (GCG)₁₀ allele. For the 1058C>T transition, 100 chromosomes were tested by PCR followed by restriction digest with MspI. The following restriction fragments are generated (in 5′-3′ order) from a normal allele: 70, 18, 22, 8, 12, 19, 127, 106, 162 and 58-bp, respectively. The 1058C>T mutation abolishes the most 3′ end restriction site generating a larger 220-bp product instead of two 162 and 58-bp products (see FIG. 2 b). Among the 100 control chromosomes tested, no 1058C>T alleles were found.

Dye terminator (Big Dye Terminator) sequencing was performed according to the instructions of the supplier of the kit (Perkin Elmer). Exon PCR products were purified using UltraCleanTM PCR Clean-up DNA purification kit (MoBio Laboratories, Inc.). All exons were sequenced in both forward and reverse directions.

Hybridisation Probe

The ARX probe for Southern blot hybridization of the deletion patient (see above) and Northern multiple tissue blots (Clontech) was generated from the 3′ untranslated region using the following primers: F, 5′-GCGAGGGCCCCAGCGTGAAG-3′-SEQ ID NO:24 and R, 5′-GCCTGTATGGAGCATTCACAC-3′-SEQ ID NO:25 (557-bp product).

GenBank Accession Numbers

PAC genomic sequence data, AC002504 and AC004655; human ARX MRNA Ensembl ID:ENSG00000004848; mouse Arx mRNA, AB006103; zebrafish Arx mRNA, AB006104, and fly aristaless protein, AAF51505.

References

The contents of the following documents are incorporated herein by reference:

-   -   1. Chelly, J. & Mandel, J. L. Monogenic causes of X-linked         mental retardation. Nat. Rev. Genet. 2, 669-680 (2001).     -   2. Berkovic, S. F. & Scheffer, I. E. Genetics of the Epilepsies.         Epilepsia 42(Suppl. 5), 16-23 (2001).     -   3. Sugawara, T. et. al. A missense mutation of the Na+ channel         alpha II subunit gene Na(v)1.2 in a patient with febrile and         agebrile seizures causes channel dysfunction. Proc. Natl. Acad.         Sci. U S A 98, 6384-6389 (2001).     -   4. Brais, B. et al. Short GCG expansions in the PABP2 gene cause         oculopharyngeal muscular dystrophy. Nat. Genet. 18, 164-167         (1998).     -   5. Gusella, J. F. & MacDonald, M. E. Molecular genetics:         unmasking polyglutamine triggers in neurodegenerative disease.         Nat. Rev. Neurosci. 1, 109-115 (2000).     -   6. Wong, M. & Trevathan, E. Infantile spasms. Pediatr. Neurol.         24, 89-98 (2001).     -   7. Vigevano, F. et al. The idiopathic form of West syndrome.         Epilepsia 34, 743-746 (1993).     -   8., Feinberg, A. P. & Leahy, W. R. Infantile spasms: case report         of sex-linked inheritance. Dev. Med. Child. Neurol. 19, 524-526.         (1977).     -   9. Bruyere, H., Lewis, S., Wood, S., MacLeod, P. J. &         Langlois, S. Confirmation of linkage in X-linked infantile         spasms (West syndrome) and refinement of the disease locus to         Xp21.3-Xp22.1. Clin. Genet. 55, 173-181 (1999).     -   10. Strømme, P. et al. X linked mental retardation and infantile         spasms in a family: new clinical data and linkage to         Xp11.4-Xp22.11. J. Med. Genet. 36, 374-378 (1999).     -   11. Claes, S. et al. The X-linked infantile spasms syndrome         (MIM 308350) maps to Xp11.4-Xpter in two pedigrees. Ann. Neurol.         42, 360-364 (1997).     -   12. Stevenson, R. E. Splitting and lumping in the nosology of         XLMR. Am. J. Med. Genet. 97, 174-182 (2000).     -   13. Partington, M. W. et al. X-linked mental retardation with         dystonic movements of the hands. Am. J. Med. Genet. 30, 251-262         (1988).     -   14. Galliot, B., de Vargas, C. & Miller, D. Evolution of         homeobox genes: Q50 Paired-like genes founded the Paired class.         Dev. Genes. Evol. 209, 186-197 (1999).     -   15. Richards, R. I. Dynamic mutations: a decade of unstable         expanded repeats in human genetic disease. Hum. Mol. Genet. 10,         2187-2194 (2001).     -   16. Miura, H., Yanazawa, M., Kato, K. & Kitamura, K. Expression         of a novel aristaless related homeobox gene ‘Arx’ in the         vertebrate telencephalon, diencephalon and floor plate. Mech.         Dev. 65, 99-109 (1997).     -   17. Ohira, R. et al. Aristaless related homeobox (ARX) gene is         expressed in a subset of neuronal precursor cells and         post-mitotic neurons in human fetal and adult brain. Am. J. Hum.         Genet. 67, Supplement 2, 169 (2000).     -   18. Meijlink, F., Beverdam, A., Brouwer, A., Oosterveen, T. C. &         Berge, D. T. Vertebrate aristaless-related genes. Int. J. Dev.         Biol. 43, 651-663 (1999).     -   19. Galliot, B. & Miller, D. Origin of anterior patterning. How         old is our head? Trends Genet. 16, 1-5. (2000).     -   20. Han, K. & Manley, J. Functional domains of the Drosophila         Engrailed protein. EMBO J. 12, 2723-2733 (1993).     -   21. Muragaki, Y., Mundlos, S., Upton, J. & Olsen, B. R. Altered         growth and branching patterns in synpolydactyly caused by         mutations in HOXD13. Science 272, 548-551 (1996).     -   22. Mundlos, S. et al. Mutations involving the transcription         factor CBFA1 cause cleidocranial dysplasia. Cell 89, 773-779         (1997).     -   23. Brown, S. A. et al. Holoprosencephaly due to mutations in         ZIC2, a homologue of Drosophila odd-paired. Nat. Genet. 20,         180-183 (-1998).     -   24. Goodman, F. R. et al. Novel HOXA13 mutations and the         phenotypic spectrum of hand-foot-genital syndrome. Am. J. Hum.         Genet. 67, 197-202 (2000).     -   25. Crisponi, L. et al. The putative forkhead transcription         factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus         inversus syndrome. Nat. Genet. 27, 159-166 (2001).     -   26. Brown, L. Y. et al. Holoprosencephaly due to mutations in         ZIC2: alanine tract expansion mutations may be caused by         parental somatic recombination. Hum. Mol. Genet. 10, 791-796         (2001).     -   27. Calado, A. et al. Nuclear inclusions in oculopharyngeal         muscular dystrophy consist of poly(A) binding protein 2         aggregates which sequester poly(A) RNA. Hum. Mol. Genet. 9,         2321-2328 (2000).     -   28. Hill, M. E. et al. Oculopharyngeal muscular dystrophy:         phenotypic and genotypic studies in a UK population. Brain 124,         522-526 (2001).     -   29. Rankin, J., Wyttenbach, A. & Rubinsztein, D. C.         Intracellular green fluorescent protein-polyalanine aggregates         are associated with cell death. Biochem. J. 348 Pt 1, 15-19         (2000).     -   30. Gaspar, C. et al. CAG tract of MJD-1 may be prone to         frameshifts causing polyalanine accumulation. Hum. Mol. Genet.         9, 1957-1966 (2000).     -   31. Banerjee-Basu, S. & Baxevanis, A. D. Molecular evolution of         the homeodomain family of transcription factors. Nucleic Acids         Res. 29, 3258-3269 (2001).     -   32. Wilson, D. S., Sheng, G., Jun, S. & Desplan, C. Conservation         and diversification in homeodomain-DNA interactions: a         comparative genetic analysis. Proc. Natl. Acad. Sci. U S A 93,         6886-6891 (1996).     -   33. Fodde R, Losekoot M.Mutation detection by denaturing         gradient gel electrophoresis (DGGE). Hum Mutat. 1994;3(2):83-94.         Review.     -   34. Leushner J. MALDI TOF mass spectrometry: an emerging         platform for genomics and diagnostics. Expert Rev Mol Diagn 2001         May;1(1):11-8. Review.     -   35. Kristensen V N, Kelefiotis D, Kristensen T, Borresen-Dale         A L. High-throughput methods for detection of genetic variation.         Biotechniques. 2001 February; 30(2):318-22. Review.     -   36. Nataraj A J, Olivos-Glander I, Kusukawa N, Highsmith W E Jr.         Single-strand conformation polymorphism and heteroduplex         analysis for gel-based mutation detection. Electrophoresis. 1999         June; 20(6):1177-85. Review.     -   37. McKenzie SE, Mansfield E, Rappaport E, Surrey S, Fortina P.         Parallel molecular genetic analysis. Eur J Hum Genet. 1998         Sep-Oct;6(5):417-29. Review. 

1-24. (canceled)
 25. A method of detecting the presence or absence of a mutation in the ARX gene comprising comparing the nucleotide sequence in a test sample with the nucleotide sequence in a control sample, wherein a difference in the nucleotide sequence in the sample indicates the presence of a mutation in the ARX gene.
 26. The method of claim 25, wherein the wild-type ARX gene comprises SEQ ID NO:1.
 27. The method of claim 25, wherein the mutation is selected from the group consisting of: an insertion of trinucleotide repeats coding for additional alanine residues within a polyalanine tract, a duplication coding for additional alanine residues within a polyalanine tract, a deletion and a missense mutation within the homeobox.
 28. The method of claim 27, wherein the test sample comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS:4, 5, 6 and
 7. 29. A method for detecting the presence or absence of an ARX-related disorder in a subject comprising comparing the nucleotide sequence in a sample obtained from the subject with a nucleotide sequence that encodes wild-type ARX, wherein a different nucleotide sequence in the sample is indicative of an ARX-related disorder.
 30. The method of claim 29, wherein the assay is selected from the group consisting of: SSCP, PCR, D.GGE, DHPLC, microarray and Southern blot-based tests.
 31. The method of claim 30, wherein a sequence comparison is made by a hybridization assay.
 32. A method for detecting the presence or absence of an ARX-related disorder in a subject comprising comparing the nucleotide or amino acid sequence of one or more ARX expression products in a sample obtained from the subject to a wild-type ARX sequence, wherein a difference in nucleotide or amino acid sequence in the sample relative to the wild-type sequence is indicative of an ARX-related disorder.
 33. The method of claim 32, wherein the expression product is mRNA.
 34. The method of claim 33, wherein the nucleotide sequence of the mRNA is determined using specific hybridization probes.
 35. The method of claim 32, wherein the sample is compared to the wild-type using an assay selected from the group consisting of: SSCP, PCR, DGGE, DHPLC, microarray and Southern blot-based tests.
 36. The method of claim 32, wherein the expression product is a polypeptide.
 37. The method of claim 36, wherein the amino acid sequence of the expression product is determined using antibodies.
 38. The method of claim 32, wherein the ARX-related disorder is selected from the group consisting of: ISSX disorders, X-linked mental retardation, X-linked myoclonic epilepsy, Partington syndrome and dystonia.
 39. The method of claim 32, wherein the difference in nucleotide sequence is an expansion of the nucleotide sequence encoding one or more of the polyalanine tracts of ARX.
 40. The method of claim 32, wherein the difference in amino acid sequence is the addition of one or more alanine residues within one or more of the polyalanine tracts of the ARX amino acid sequence.
 41. A method for diagnosing an ARX-related disorder comprising comparing the expression level of one or more ARX expression products obtained from a sample to a wild-type ARX expression level, wherein a difference in expression level in the sample relative to the wild-type expression level is indicative of an ARX-related disorder.
 42. The method of claim 41, wherein the expression product is mRNA.
 43. A method for predicting the likelihood that an individual will have an ARX-related disorder, wherein a nucleic acid sample obtained from the individual is analyzed by determining the nucleotide sequence at the polymorphic sites of SEQ ID NOS:4, 5, 6 and 7, and wherein if the sample obtained from the individual has the sequence of either SEQ ID NO:4, 5, 6 or 7 at one or more polymorphic sites, then the individual from whom the sample was obtained is likely to have an ARX-related disorder.
 44. The method of claim 43, wherein the nucleic acid sample is an mRNA sample.
 45. The method of claim 44, wherein the nucleotide sequence of the mRNA is determined using specific hybridization probes.
 46. The method of claim 43, wherein the sample is analyzed using an assay selected from the group consisting of: SSCP, PCR, DGGE, DHPLC, microarray and Southern blot-based tests.
 47. The method of claim 43, wherein the ARX-related disorder is selected from the group consisting of: ISSX disorders, X-linked mental retardation, X-linked myoclonic epilepsy, Partington syndrome and dystonia.
 48. A method for predicting the likelihood that an individual will have an ARX-related disorder, wherein a sample obtained from the individual is analyzed by determining the amino acid sequence of the ARX-encoded polypeptide at the polymorphic sites of SEQ ID NOS:8, 9, 10 and 11, and wherein if the sample obtained from the individual has the sequence of either SEQ ID NO:8, 9, 10 or 11 at one or more polymorphic sites, then the individual from whom the sample was obtained is likely to have an ARX-related disorder.
 49. The method of claim 48, wherein the amino acid sequence of the polypeptide is determined using antibodies.
 50. The method of claim 48, wherein the ARX-related disorder is selected from the group consisting of: ISSX disorders, X-linked mental retardation, X-linked myoclonic epilepsy, Partington syndrome and dystonia.
 51. A nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3.
 52. A nucleic acid molecule that hybridizes under stringent conditions with a DNA molecule comprising the nucleotide sequence of SEQ ID NO:
 1. 53. A nucleic acid molecule that encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:2.
 54. A polypeptide comprising the amino acid sequence of SEQ ID NO:2.
 55. An antibody to a polypeptide of claim
 54. 56. A nucleic acid encoding an altered ARX polypeptide, wherein the function of the altered ARX polypeptide has been altered or destroyed.
 57. A nucleic acid molecule comprising the nucleotide sequence selected from the group consisting of: SEQ ID NOS:4, 5, 6 and
 7. 58. An altered ARX polypeptide whose function has been altered or destroyed.
 59. A polypeptide comprising an amino acid sequence selected from the group consisting of: SEQ ID NOS:8, 9, 10 and
 11. 60. An animal model in which the ARX gene is knocked out. 